166 related articles for article (PubMed ID: 33043714)
1. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
Zhang T; Rao J; Li W; Wang K; Qiu F
Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
3. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions.
Wang K; Gao Q; Zhang T; Rao J; Ding L; Qiu F
Drug Metab Rev; 2020 May; 52(2):235-257. PubMed ID: 32406758
[TBL] [Abstract][Full Text] [Related]
5. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Karkhanis A; Lam HY; Venkatesan G; Koh SK; Chai CL; Zhou L; Hong Y; Kojodjojo P; Chan EC
Biochem Pharmacol; 2016 May; 107():67-80. PubMed ID: 26972388
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
Kamel A; Harriman S
Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation.
Tang LWT; Chan ECY
Biochem Pharmacol; 2022 Dec; 206():115336. PubMed ID: 36332675
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K
Drug Metab Dispos; 2007 Feb; 35(2):246-55. PubMed ID: 17093004
[TBL] [Abstract][Full Text] [Related]
10. Enzyme Activity of Natural Products on Cytochrome P450.
Zuo HL; Huang HY; Lin YC; Cai XX; Kong XJ; Luo DL; Zhou YH; Huang HD
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056827
[TBL] [Abstract][Full Text] [Related]
11. Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.
Rendic SP; Guengerich FP
Arch Toxicol; 2021 Feb; 95(2):395-472. PubMed ID: 33459808
[TBL] [Abstract][Full Text] [Related]
12. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C.
Kim SB; Kang HE; Cho HJ; Kim YS; Chung SJ; Yoon IS; Kim DD
Drug Dev Ind Pharm; 2016; 42(2):263-9. PubMed ID: 26133083
[TBL] [Abstract][Full Text] [Related]
13. Prediction of seriniquinone-drug interactions by in vitro inhibition of human cytochrome P450 enzymes.
Moreira da Silva R; Carrão DB; Habenschus MD; Jimenez PC; Lopes NP; Fenical W; Costa-Lotufo LV; de Oliveira ARM
Toxicol In Vitro; 2020 Jun; 65():104820. PubMed ID: 32142840
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights.
Mirzaei MS; Ivanov MV; Taherpour AA; Mirzaei S
Chem Res Toxicol; 2021 Apr; 34(4):959-987. PubMed ID: 33769041
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
Hollenberg PF; Kent UM; Bumpus NN
Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
18. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
19. Reversible and Irreversible Inhibition of Cytochrome P450 Enzymes by Methylophiopogonanone A.
Tu DZ; Mao X; Zhang F; He RJ; Wu JJ; Wu Y; Zhao XH; Zheng J; Ge GB
Drug Metab Dispos; 2020 Jun; 49(6):459-469. PubMed ID: 33811108
[TBL] [Abstract][Full Text] [Related]
20. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
